ArticleTransplantation direct2026
Less Invasive Acute Rejection Surveillance After Pediatric Heart Transplantation: Experiences From a Low-intensity Biopsy Center.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute rejection remains a leading cause of morbidity and mortality early after pediatric heart transplantation (HT). Current guidelines recommend only endomyocardial biopsies (EMB) as reliable for rejection surveillance. We purposed to explore clinical outcomes of less invasive rejection surveillance in a low-intensity biopsy center in pediatric heart recipients. Methods: We retrospectively analyzed data from 46 pediatric heart recipients (median age 5.7 y; interquartile range [IQR], 2.5-8.0) discharged between 2011 and 2021. Clinical and echocardiographic evaluations were performed frequently, whereas protocol-based routine EMB were scheduled only at 1 and 2 y post-HT. Additional biopsies were performed if new-onset symptoms and/or a decline in graft function, as assessed by echocardiography, including tissue Doppler imaging (TDI)-derived velocities, were detected. Results: Graft survival was not compromised by less invasive surveillance with 97.8% at 1 y and 95.7% at 2 y post-HT. A total of 680 echocardiograms (median 15 per recipient; IQR, 13-17) and 140 biopsies (median 3 per recipient; IQR, 2-4) were analyzed. Acute rejection (4 acute cellular rejection and 8 antibody-mediated rejection) was found in 8.5% of the EMB. None of the protocol-based routine EMB of asymptomatic patients revealed rejection. Absence of a reduction in TDI-derived left ventricular and interventricular septal systolic velocities, combined with clinical evaluation, correlated with nonrejection. Conclusions: Combining frequent clinical follow-up with echocardiographic assessment using TDI as a less invasive method of rejection surveillance did not compromise long-term clinical outcomes. Validated in larger pediatric cohorts, it could save invasive biopsies, reducing the risk of biopsy-related complications and medical costs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.